Medifast (MED) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue declined 43.1% year-over-year to $168.6M, driven by a 36.2% drop in active earning OPTAVIA Coaches and lower productivity per Coach.

• Net loss for Q2 2024 was $8.2M, or $0.75 per diluted share, compared to net income of $30.3M, or $2.77 per share, in Q2 2023; non-GAAP adjusted net income was $10.1M, or $0.92 per share.

• The company is undergoing a business transformation, including partnerships, new product launches for GLP-1 users, and a collaboration with LifeMD, supported by a $25M marketing campaign.

• Gross profit margin improved to 73.2% from 71.1% last year, aided by cost savings and inventory efficiencies.

• Company remains debt-free with $163.5M in cash and investments at quarter-end.

Financial highlights

• Q2 2024 revenue: $168.6M, a 43.1% decrease year-over-year; gross profit: $123.4M, down 41.4% year-over-year.

• Gross margin improved 210 bps to 73.2%; non-GAAP adjusted gross profit: $126M, margin up 370 bps to 74.8%.

• Net loss: $8.2M ($0.75 per diluted share); non-GAAP adjusted net income: $10.1M ($0.92 per diluted share).

• SG&A expenses fell 23.7% to $131.3M, but as a percentage of revenue increased to 77.9%.

• Cash, cash equivalents, and investments: $163.5M at quarter end.

Outlook and guidance

• Q3 2024 revenue expected between $125M and $145M; diluted loss per share projected between $0.05 and $0.70, excluding certain LifeMD-related costs and investment gains/losses.

• Marketing spend for 2024 revised down to $25M from $30M, aligning with product launch timing.

• Management expects continued short-term pressure on customer acquisition and active Coach count due to competitive dynamics, especially from GLP-1 medications.

• Anticipates top-line improvement from late 2024 into 2025 as new initiatives gain traction.